Literature DB >> 19304942

Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation.

Nicholas J Leeper1, Maureen M Tedesco, Yoko Kojima, Geoffrey M Schultz, Ramendra K Kundu, Euan A Ashley, Phillip S Tsao, Ronald L Dalman, Thomas Quertermous.   

Abstract

Apelin is a potent inodilator with recently described antiatherogenic properties. We hypothesized that apelin might also attenuate abdominal aortic aneurysm (AAA) formation by limiting disease-related vascular wall inflammation. C57BL/6 mice implanted with osmotic pumps filled with apelin or saline were treated with pancreatic elastase to create infrarenal AAAs. Mice were euthanized for aortic PCR analysis or followed ultrasonographically and then euthanized for histological analysis. The cellular expression of inflammatory cytokines and chemokines in response to apelin was also assessed in cultured macrophages, smooth muscle cells, and fibroblasts. Apelin treatment resulted in diminished AAA formation, with a 47% reduction in maximal cross-sectional area (0.74 vs. 1.39 mm(2), P < 0.03) and a 57% reduction in macrophage infiltrate (113 vs. 261.3 cells/high-power field, P < 0.0001) relative to the saline-treated group. Apelin infusion was also associated with significantly reduced aortic macrophage colony-stimulating factor expression and decreased monocyte chemattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1alpha, interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha mean mRNA levels. Apelin stimulation of cultured macrophages significantly reduced MCP-1 and TNF-alpha mRNA levels relative to baseline (2.03- and 1.89-fold reduction, P < 0.03, respectively) but did not affect intimal adhesion molecule expression or medial or adventitial cell cytokine production. Apelin significantly reduces aneurysm formation in the elastase model of human AAA disease. The mechanism appears to be decreased macrophage burden, perhaps related to an apelin-mediated decrease in proinflammatory cytokine and chemokine activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19304942      PMCID: PMC2685356          DOI: 10.1152/ajpheart.01341.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  30 in total

1.  Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo.

Authors:  Junji Ishida; Tatsuo Hashimoto; Yasumi Hashimoto; Shiro Nishiwaki; Taku Iguchi; Shuichi Harada; Takeshi Sugaya; Hitomi Matsuzaki; Rie Yamamoto; Naotaka Shiota; Hideki Okunishi; Minoru Kihara; Satoshi Umemura; Fumihiro Sugiyama; Ken-Ichi Yagami; Yoshitoshi Kasuya; Naoki Mochizuki; Akiyoshi Fukamizu
Journal:  J Biol Chem       Date:  2004-04-15       Impact factor: 5.157

2.  Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm.

Authors:  P K Shah
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

3.  Prognosis of abdominal aortic aneurysms. A population-based study.

Authors:  M P Nevitt; D J Ballard; J W Hallett
Journal:  N Engl J Med       Date:  1989-10-12       Impact factor: 91.245

4.  Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells.

Authors:  Matthias J Kleinz; Jeremy N Skepper; Anthony P Davenport
Journal:  Regul Pept       Date:  2005-03-30

5.  The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.

Authors:  Euan A Ashley; Jennifer Powers; Mary Chen; Ramendra Kundu; Tom Finsterbach; Anthony Caffarelli; Alicia Deng; Jens Eichhorn; Raina Mahajan; Rani Agrawal; Joan Greve; Robert Robbins; Andrew J Patterson; Daniel Bernstein; Thomas Quertermous
Journal:  Cardiovasc Res       Date:  2005-01-01       Impact factor: 10.787

6.  Hemodynamic regulation of CD34+ cell localization and differentiation in experimental aneurysms.

Authors:  Eiketsu Sho; Mien Sho; Hiroshi Nanjo; Koichi Kawamura; Hirotake Masuda; Ronald L Dalman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-19       Impact factor: 8.311

7.  Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells.

Authors:  Matthias J Kleinz; Anthony P Davenport
Journal:  Regul Pept       Date:  2004-05-15

Review 8.  Mouse models of abdominal aortic aneurysms.

Authors:  Alan Daugherty; Lisa A Cassis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-01-22       Impact factor: 8.311

9.  Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.

Authors:  Shlomo Keidar; Marielle Kaplan; Elsa Pavlotzky; Raymond Coleman; Tony Hayek; Shadi Hamoud; Michael Aviram
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

10.  Apelin has in vivo inotropic effects on normal and failing hearts.

Authors:  Mark F Berry; Timothy J Pirolli; Vasant Jayasankar; Jeffrey Burdick; Kevin J Morine; Timothy J Gardner; Y Joseph Woo
Journal:  Circulation       Date:  2004-09-14       Impact factor: 29.690

View more
  53 in total

Review 1.  Apelin and insulin resistance: another arrow for the quiver?

Authors:  Shiming Xu; Philip S Tsao; Patrick Yue
Journal:  J Diabetes       Date:  2011-09       Impact factor: 4.006

2.  Quantitative estimates of the variability of in vivo sonographic measurements of the mouse aorta for studies of abdominal aortic aneurysms and related arterial diseases.

Authors:  Uchechukwu K Sampson; Prudhvidhar R Perati; Petra A Prins; Wellington Pham; Zhouwen Liu; Frank E Harrell; MacRae F Linton; John C Gore; Valentina Kon; Sergio Fazio
Journal:  J Ultrasound Med       Date:  2011-06       Impact factor: 2.153

3.  Drug discovery in a multidimensional world: systems, patterns, and networks.

Authors:  Joel T Dudley; Eric Schadt; Marina Sirota; Atul J Butte; Euan Ashley
Journal:  J Cardiovasc Transl Res       Date:  2010-07-31       Impact factor: 4.132

4.  Modulation of the apelin/APJ system in heart failure and atherosclerosis in man.

Authors:  Sarah L Pitkin; Janet J Maguire; Rhoda E Kuc; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 5.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

6.  Nicotine induces pro-inflammatory response in aortic vascular smooth muscle cells through a NFκB/osteopontin amplification loop-dependent pathway.

Authors:  Yongyi Wang; Fei Zhang; Wengang Yang; Song Xue
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

Review 7.  Adipose tissue and vascular inflammation in coronary artery disease.

Authors:  Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò
Journal:  World J Cardiol       Date:  2014-07-26

Review 8.  Apelin, diabetes, and obesity.

Authors:  Isabelle Castan-Laurell; Cédric Dray; Camille Attané; Thibaut Duparc; Claude Knauf; Philippe Valet
Journal:  Endocrine       Date:  2011-08       Impact factor: 3.633

9.  Increased bone mass in mice lacking the adipokine apelin.

Authors:  Lalita Wattanachanya; Wei-Dar Lu; Ramendra K Kundu; Liping Wang; Marcia J Abbott; Dylan O'Carroll; Thomas Quertermous; Robert A Nissenson
Journal:  Endocrinology       Date:  2013-04-12       Impact factor: 4.736

Review 10.  Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells.

Authors:  Giovanni Anfossi; Isabella Russo; Gabriella Doronzo; Alice Pomero; Mariella Trovati
Journal:  Mediators Inflamm       Date:  2010-06-28       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.